Another retrospective study of 76 patients with metastatic renal cell carcinoma revealed that concomitant use of bisphosphonates and EGFR-TKIs in renal cell carcinoma patients with bone metastases probably improved treatment efficacy [17]. The gene discussed is EGFR; the disease is hereditary clear cell renal cell carcinoma.